AveXis' IPO

AveXis raised a round of funding on February 11, 2016. Investors include Public.

AveXis is a clinical-stage gene therapy company developing treatments for rare and life-threatening neurological genetic diseases. The company's initial product candidate, scAAV9.CB.SMN, is in an ongo…

Articles about AveXis' IPO: